A Phase 1/2 interventional study of Arm A and Arm B in Colorectal Cancer Metastatic to Liver, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 21 open to participants now, 22 under way, 1 of them phase 3. Colorectal Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
Among the 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 20 of the 21 other live ones, and was the 25th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →21 of the 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 1
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 102 across the 17 interventional studies, 569 across the 10 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.
2 of the studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05730595Cancer Institute and Hospital, Chinese Academy of Medical SciencesFluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer | 2026-12-01 |
| NCT06904677Cancer Institute and Hospital, Chinese Academy of Medical SciencesUsing 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Colorectal Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if QL1706 (Iparomlimab/ Tuvonralimab)+ chemotherapy+ cetuximab/bevacizumab works to treat potentially resectable colorectal cancer patients with liver metastases in adults. It will also learn about the safety of this therapeutic regimen. The main questions it aims to answer are: Does QL1706+ Chemotherapy+ Cetuximab/Bevacizumab improve the 18-month progression free survival (PFS) rate of participants?
The study plans to enroll 90-102 patients, who will be divided into 2 arms based on the primary tumor location and genetic status.
Arm A: Patients with primary tumors located in the left colorectum and RAS ( Rat Sarcoma Virus ) and BRAF ( V-raf Murine Sarcoma Viral Oncogene Homolog B ) wild-type.
Arm B: Patients with primary tumors located in the right colorectum and/or RAS or BRAF mutant
The study consists of two phases: phase Ib ( safety run-in phase ) and phase II.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with primary tumors located in the left colorectum and RAS and BRAF wild-type will receive QL1706 Combined with mFOLFOX6 and Cetuximab
Drug: Arm A
Participants with primary tumors located in the right colorectum and/or RAS or BRAF mutant will receive QL1706 Combined with FOLFOXIRI and Bevacizumab
Drug: Arm B
QL1706 3mg/kg, IV, D1, Q2W, for a maximum of 2 years. mFOLFOX6 : Oxaliplatin 85 mg/m², IV, D1, Q2W, for a maximum of 12 cycles. LV 400mg/m², IV, D1, Q2W, for a maximum of 2 years. 5-FU 400mg/m², IV, D1; followed by a continuous intravenous infusion of 1200mg/(m²•d) for 2 days (total dose 2400mg/m², infusion duration 46-48 hours), Q2W, for a maximum of 2 years. Cetuximab 500mg/m², IV, D1, Q2W, for a maximum of 2 years.
QL1706 3mg/kg, IV, D1, Q2W, for a maximum of 2 years FOLFOXIRI : Irinotecan 150mg/m², IV, D1, Q2W, for a maximum of 12 cycles Oxaliplatin 85mg/m², IV, D1, Q2W, for a maximum of 12 cycles LV 400mg/m², IV, D1, Q2W, for a maximum of 2 years 5-FU (total dose: 2400mg/m²) via continuous intravenous infusion for 48 hours, D1, Q2W, for a maximum of 2 years Bevacizumab 5mg/kg, IV, D1, Q2W, for a maximum of 2 years
18-month Progression-Free Survival (PFS) rate in phase II
18-month PFS rate is defined as the proportion of participants who are alive and progression free at 18 months from start of study treatment. Assessed according to RECIST v1.1 by investigator.
Time frame: From enrollment to 18 months after enrollment
safety in phase Ib
Determine frequency and severity of adverse events as assessed by NCI-CTCAE v5.0
Time frame: From enrollment to 18 months after enrollment
R0/R1 resection rate
Time frame: From enrollment to 18 months after enrollment
Objective Response Rate (ORR)
Time frame: From enrollment to 18 months after enrollment
Progression-Free Survival (PFS)
Time frame: From enrollment to 18 months after enrollment
Time to Response (TTR)
Time frame: From enrollment to 18 months after enrollment
Disease Control Rate (DCR)
Time frame: From enrollment to 18 months after enrollment
18-Month/24-Month No Evidence of Disease (NED) Rate
Time frame: From enrollment to 24 months after enrollment
Adverse Event
Time frame: From enrollment to 24 months after enrollment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for May 2029, 32 months later.
Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 32 months is below that.
Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences →